# Peter G. Rose

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-g-rose/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,573 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 65 |
| i10-index | 211 |
| Last Known Institution | Cleveland Clinic |
| OpenAlex ID | https://openalex.org/A5005911289 |
| ORCID iD | 0000-0003-2676-0166 |
| Works | 440 |

## Researcher papers

- [Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer](https://scholariq.org/papers/concurrent-cisplatin-based-radiotherapy-and-chemotherapy-for-locally-advanced/)
- [Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/prognostic-factors-for-stage-iii-epithelial-ovarian-cancer-a-gynecologic/)
- [Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/tumor-residual-after-surgical-cytoreduction-in-prediction-of-clinical-outcome-in/)
- [Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.](https://scholariq.org/papers/prolonged-oral-etoposide-as-second-line-therapy-for-platinum-resistant-and/)
- [Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma](https://scholariq.org/papers/secondary-surgical-cytoreduction-for-advanced-ovarian-carcinoma/)
- [Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study](https://scholariq.org/papers/fixed-dose-rate-gemcitabine-plus-docetaxel-as-second-line-therapy-for-metastatic/)
- [Positron Emission Tomography for Evaluating Para-aortic Nodal Metastasis in Locally Advanced Cervical Cancer Before Surgical Staging: A Surgicopathologic Study](https://scholariq.org/papers/positron-emission-tomography-for-evaluating-para-aortic-nodal-metastasis-in/)
- [Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial](https://scholariq.org/papers/durvalumab-plus-carboplatin-paclitaxel-followed-by-maintenance-durvalumab-with/)
- [Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer](https://scholariq.org/papers/phase-ii-study-of-liposomal-doxorubicin-in-platinum-and-paclitaxel-refractory/)
- [Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-ii-trial-of-bevacizumab-in-recurrent-or-persistent-endometrial-cancer-a/)
- [Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-1-2016-nccn-clinical-practice-guidelines-in-oncology/)
- [Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial](https://scholariq.org/papers/prospective-evaluation-of-the-tolerability-and-efficacy-of-niraparib-dosing/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)

## Researcher university

- [Cleveland Clinic](https://scholariq.org/institutions/cleveland-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.